Global Health Status News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Global health status. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Global Health Status Today - Breaking & Trending Today

Atezolizumab Plus Cabozantinib Improves PFS Over Novel Hormonal Therapy in mCRPC

A significant progression-free survival improvement was achieved with cabozantinib plus atezolizumab vs second-line novel hormonal therapy in mCRPC. ....

Neeraj Agarwal , Global Health Status , University Of Utah , European Organization For Research , Genitourinary Oncology Gu Program , Huntsman Cancer Institute , Genitourinary Oncology , Investigational Therapeutics , European Organization , Cancer Quality , Cabozantinib Plus Atezolizumab , Metastatic Castration Resistant Prostate Cancer , 2024 Genitourinary Cancers Symposium , Phase 3 Contact 02 Trial ,

Cabometyx, Tecentriq Combo Improves Time to Progression in mCRPC

Cabometyx plus Tecentriq led to improved progression-free survival compared with novel hormonal therapy in patients with metastatic castration-resistant prostate cancer. ....

Neeraj Agarwal , Cabometyx Tecentriq , Global Health Status , European Organization For Research , University Of Utah , Genitourinary Oncology Gu Program , Huntsman Cancer Institute , Genitourinary Oncology , Investigational Therapeutics , European Organization , Cancer Quality , Global Health , Prostate Cancer , Metastatic Castration Resistant Prostate Cancer , Asco Gu24 ,

Quizartinib Plus Chemotherapy Improved OS in Patients with AML, Little Hindrance to QOL

Compared to placebo plus chemotherapy, quizartinib plus chemotherapy improved OS without significant AEs and impact on QOL in patients with AML. ....

United States , San Diego , Mikkaela Sekeres , European Organization For Research , Sylvester Comprehensive Cancer Center , Global Health Status , American Society Of Hematology , American Society , European Organization , Sylvester Comprehensive Cancer ,

EMA Validates Application for Frontline Nivolumab Plus Chemo in Advanced Urothelial Cancer

The European Medicines Agency has validated a type II variation application for the first-line combination of nivolumab and cisplatin-based chemotherapy for adult patients with unresectable or metastatic urothelial carcinoma. ....

Dana Walker , Global Health Status , European Union , Bristol Myers Squibb , European Medicines Agency , New England Journal , Health Status , Medicines Agency , Bristol Myers , Nivolumab And Cisplatin Based Chemotherapy , Patients With Unresectable Or Metastatic Urothelial Carcinoma ,